Global Orphan Drug Sector Poised for Growth Amidst Unmet Rare Disease Needs
05 avr. 2024 04h04 HE
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Global Orphan Drug Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study provides critical insights into the...
Rare Disease Treatment Market to Achieve USD 228.34 Billion by 2028, Showcasing a Compound Annual Growth Rate of 11.08%
02 févr. 2024 10h52 HE
|
Research and Markets
Dublin, Feb. 02, 2024 (GLOBE NEWSWIRE) -- The "Global Rare Disease Treatment Market (2023-2028) by Therapeutic Area, Drug Type, Drug Class, Mode of Administration, Distribution Channel, and...
Global Orphan Drugs Research Analysis Report 2023: Growing Approvals of Innovative Orphan Drugs Propel Market Expansion, Biologics Lead the Way - Forecasts to 2034
31 janv. 2024 11h22 HE
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Global Orphan Drugs Market Analysis & Forecast 2024-2034: Market By Drug Type; By Therapy; By Distribution Channel; and By Region" report has been...
Paroxysmal Nocturnal Hemoglobinuria Treatment Advances with Comprehensive Danicopan Market Forecast to 2032
24 janv. 2024 10h44 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Danicopan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The global healthcare...
Emerging Trends in the Orphan Drugs Industry, 2023-2028: Worldwide Market Analysis Featuring Profiles of Leading Players AstraZeneca, Eisai, Bristol Myers Squibb, and Pfizer Among Others
17 janv. 2024 10h03 HE
|
Research and Markets
Dublin, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The "Global Markets for Orphan Drugs" report has been added to ResearchAndMarkets.com's offering. The global orphan drugs market was valued at an...
AB Science reçoit un avis d’acceptation pour le brevet européen couvrant le masitinib jusqu’en 2036 dans le traitement de la mastocytose
15 janv. 2024 12h07 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET EUROPÉEN COUVRANT LE MASITINIB JUSQU'EN 2036 DANS LE TRAITEMENT DE LA MASTOCYTOSE CETTE DÉCISION RENFORCE LA STRATÉGIE DE...
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
15 janv. 2024 12h07 HE
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS THIS DECISION FURTHER STRENGTHENS MASITINIB’S INTELLECTUAL...
Orphan Drug Market Size Worth USD 488.53 Billion in 2032 | Emergen Research
08 janv. 2024 08h59 HE
|
Emergen Research
Vancouver, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % during the forecast period....
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
21 déc. 2023 16h00 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of...
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
27 nov. 2023 09h00 HE
|
Biodexa Pharmaceuticals PLC
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to...